Abstract: Treatment modalities for newly diagnosed advanced ovarian cancer include primary debulking surgery （PDS） and neoadjuvant chemotherapy combined with interval debulking surgery（NACT-IDS）. The role of NACT in the treatment of advanced epithelial ovarian cancer has long been controversial. On the one hand，it increases the rate of optimal cytoreduction while reducing perioperative complications. On the other hand，its impact on prognosis is vague and it may lead to platinum-resistance. Therefore，it is of great significance to choose optimal candidates for NACT. The traditional models to predict R0 resection of ovarian cancer is mainly composed of CT-based Suidan criteria and Fagotti laparoscopic score. Fudan University Shanghai Cancer Center recommends a Fudan criteria with higher predictive ability based on DWI/MR. Regardless of whether NACT is prescribed or not，R0 resection is an independent prognostic factor for ovarian cancer，which should be pursued tirelessly by gynecologic oncologists.

Key words: ovarian cancer, neoadjuvant chemotherapy, pre-operative evaluation

摘要： 晚期上皮性卵巢癌初始治疗模式包括初始肿瘤细胞减灭术（PDS）和新辅助化疗联合间歇性肿瘤细胞减灭术（NACT-IDS）。NACT在晚期上皮性卵巢癌中的治疗作用一直存在诸多争议，一方面其可提高满意减瘤率并降低围术期并发症，而另一方面其对预后影响尚不肯定，且可能导致铂类耐药，所以选择NACT需谨慎筛选合适患者。传统评估卵巢癌R0切除的预测模型主要有基于CT的Suidan评分和基于腹腔镜的Fagotti评分，复旦大学附属肿瘤医院基于DWI/MR构建了预测能力更高的“复旦评分”。无论是否行NACT，R0切除都是卵巢癌的独立预后因素，临床医生需尽最大努力达手术R0。

关键词: 卵巢癌, 新辅助化疗, 术前评估